title: Intratympanic injection in delayed endolymphatic hydrops.
abstract: CONCLUSIONS
  The present study showed that intratympanic dexamethasone injection (ITD) is a promising approach for the treatment of contralateral and ipsilateral delayed endolymphatic hydrops (DEH). Moreover, intratympanic gentamicin injection (ITG), as a chemical labyrinthectomy, is a simple alternative for controlling vertigo in patients with ipsilateral DEH.
  
  
  OBJECTIVE
  This study examined the effect of ITD or ITG on DEH.
  
  
  METHODS
  Fourteen patients with DEH completed the clinical and audio-vestibular evaluation. Among them, 10 cases (ipsilateral type: nine cases, contralateral type: one case) were treated with intratympanic injection. Four patients with ipsilateral DEH underwent ITG, five patients with ipsilateral type and one patient with contralateral type received ITD. All 10 cases were followed up for 8-48 months.
  
  
  RESULTS
  Complete and substantial vertigo control was achieved in four of nine ipsilateral DEH patients treated with ITG. In the other five ipsilateral cases who received ITD, two accomplished complete vertigo control and two had substantial control. In one case, the vertigo was not effectively controlled. One case of contralateral DEH underwent ITD and this case had complete vertigo control. The vertigo intensity, vertigo frequency, vertigo duration and the functional level scale after intratympanic injection was decreased significantly.
authors.affiliation: Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei Province , PR China.
authors.forename: Bo
authors.initials: B
authors.lastname: Liu
authors.forename: Sulin
authors.initials: S
authors.lastname: Zhang
authors.forename: Yangming
authors.initials: Y
authors.lastname: Leng
authors.forename: Renhong
authors.initials: R
authors.lastname: Zhou
authors.forename: Jingjing
authors.initials: J
authors.lastname: Liu
authors.forename: Weijia
authors.initials: W
authors.lastname: Kong
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001299:Audiometry; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D018159:Endolymphatic Hydrops / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D000069555:Injection, Intratympanic; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014717:Vertigo / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D014722:Vestibule, Labyrinth / Q000187:drug effects / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D005938:Glucocorticoids; D003907:Dexamethasone
keywords: Endolymphatic hydrops; dexamethasone; gentamicin; injection; inner ear